| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
10,590,000 |
| Market
Cap: |
3.18(K) |
| Last
Volume: |
13,822,625 |
Avg
Vol: |
11,146,411 |
| 52
Week Range: |
$0.0002 - $0.055675 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Viveve Medical is a holding company. Through its subsidiaries, Co. designs, develops, manufactures and markets a platform medical technology, which it refers to as Cryogen-cooled Monopolar Radiofrequency (CMRF). Co.'s proprietary CMRF technology is delivered through a radiofrequency generator, handpiece and treatment tip, that collectively, Co. refers to as the Viveve® System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence depending on the relevant country-specific clearance or approval, that Co. refers to as the Viveve treatment.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tauscher Mark R |
Presidence and CEO |
• • – |
2008-03-11 |
4 |
A |
$0.38 |
$5,510 |
D/D |
14,500 |
148,568 |
|
- |
|
| Rudko Robert I |
Chief Scientific Officer |
• • – |
2007-12-06 |
4 |
S |
$0.43 |
$430 |
D/D |
(1,000) |
1,091,862 |
|
- |
|
| Rudko Robert I |
Chief Scientific Officer |
• • – |
2007-12-06 |
4 |
S |
$0.41 |
$830 |
D/D |
(2,000) |
1,092,862 |
|
- |
|
| Rudko Robert I |
Chief Scientific Officer |
• • – |
2007-12-05 |
4 |
S |
$0.41 |
$410 |
D/D |
(1,000) |
1,094,862 |
|
- |
|
| Rudko Robert I |
Chief Scientific Officer |
• • – |
2007-12-05 |
4 |
S |
$0.41 |
$410 |
D/D |
(1,000) |
1,095,862 |
|
- |
|
| Pendergast Edward H |
Director |
– • – |
2007-06-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,000 |
62,492 |
|
- |
|
| Adams Michael F |
VP, New VenturesOfficer |
• – – |
2005-03-16 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
128,344 |
|
- |
|
| Luppi Kenneth J |
VP,Operations & Development |
• – – |
2004-06-04 |
4 |
S |
$0.93 |
$3,726 |
D/D |
(4,000) |
5,067 |
|
- |
|
| Luppi Kenneth J |
VP, Operations and Development |
• – – |
2004-05-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,067 |
|
- |
|
| Adams Michael F |
VP, QA/RA and New VenturesOffi |
• – – |
2004-05-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
158,334 |
|
- |
|
| Rudko Robert I |
Chief Scientific Officer |
• • – |
2004-03-05 |
4/A |
S |
$1.51 |
$7,550 |
I/I |
(5,000) |
1,096,862 |
|
- |
|
| Rudko Robert I |
Chief Scientific Officer |
• • – |
2004-03-02 |
4 |
S |
$1.46 |
$7,297 |
I/I |
(5,000) |
1,096,862 |
|
- |
|
| Rudko Robert I |
Chief Scientific Officer |
• • – |
2004-03-02 |
4 |
S |
$1.42 |
$7,113 |
D/D |
(5,000) |
1,101,862 |
|
- |
|
| Rudko Robert I |
Chief Scientific Officer |
• • – |
2003-11-11 |
4 |
S |
$1.45 |
$7,250 |
I/I |
(5,000) |
1,106,862 |
|
- |
|
| Tauscher Mark R |
Chief Executive Officer |
• • – |
2003-06-02 |
5 |
B |
$0.48 |
$11,594 |
D/D |
23,930 |
134,068 |
|
- |
|
165 Records found
|
|
Page 7 of 7 |
|
|
